The government is considering increasing healthcare costs to save 700 million euros by imposing a deductible at pharmacies and doubling the caps.
At the dawn of 2025, the French healthcare system finds itself at a crossroads between maintaining quality of care and budgetary imperatives. To improve its finances, the government proposes a major reform aimed at increasing the costs borne by patients by doubling the annual ceilings of medical deductibles and flat-rate contributions, as well as imposing direct payment of deductibles at pharmacy counters. These measures aim to save 700 million euros in the upcoming fiscal year, while seeking to make users more responsible. Nevertheless, this strategy has elicited mixed reactions among healthcare professionals, patient associations, and actors in the pharmaceutical sector, including major laboratories like Sanofi, Pfizer, and Roche.
Among the targeted measures is the deductible on medicines, whose proposed payment method will significantly change the patient’s journey. This reform is part of a broader context of controlling public healthcare expenses, with recovery targets set in the billions of euros. Debates are heating up around the balance between necessary savings and equitable access to care, raising questions about the actual impact for citizens, especially the most vulnerable.
Doubling of the medical deductibles ceiling: mechanisms and implications for patients
The government plans to raise the annual ceiling of medical deductibles from 50 to 100 euros per insured, a doubling that also applies to the flat-rate contributions, whose combined annual ceilings could reach 200 euros per person. This increase marks a turning point in healthcare funding policy, where Social Security reduces its reimbursement share, automatically increasing the remaining out-of-pocket costs for users.
The deductibles concern a wide range of expenses: medicines, medical consultations, paramedical care, radiological examinations and biological analyses, as well as medical transportation. Concretely, this means that a patient previously paid around 100 euros maximum per year for these deductibles. Starting in 2025, for the same volume of care, this amount could double, potentially reaching 200 euros, which weighs more heavily on household budgets.
It should be noted that these deductibles are not covered by the so-called “responsible” supplementary insurance contracts, which cover more than 98 % of health mutuals. This means that despite having supplementary insurance, these deductibles remain the actual responsibility of patients, representing a clear withdrawal of support from Health Insurance. This mechanism primarily aims to make insured individuals more responsible in their medical consumption, encouraging more thoughtful use of care.
Current functioning of deductibles: practices with pointed limits
Traditionally, medical deductibles are indirectly deducted from reimbursements made by Social Security. The insured does not pay an additional amount at the pharmacy or during consultations but notices a slight deduction on their reimbursements. This operational mode has the advantage of administrative simplicity but does not create a visible reference for the patient on the actual cost of their care.
This system has fostered a certain perception of “illusion of everything being free,” criticized by several actors such as employers and the government. The absence of an explicit disbursement penalizes, according to them, the responsible behavior of insured individuals, who sometimes tend to consume care that is not strictly necessary.
The proposed reform aims to correct this by making the payment at the counter visible, just like the purchase price of medicines. This transformation could alter behaviors by introducing a financial friction during the purchase or medical visit, thereby limiting excessive spending.
| Current | 2025 Proposal | Impact for the patient |
|---|---|---|
| Annual ceiling of medical deductibles | 50 € | Rise to 100 €, doubling |
| Annual ceiling of flat-rate contributions | 50 € | Rise to 100 €, also doubling |
| Deductibles reimbursed by responsible mutual insurance | No | No change, remaining actual out-of-pocket cost |
| Indirect payment via Health Insurance | Direct payment at pharmacy counter envisaged | More visible and concrete for the user |
Economic impact on the healthcare system and expenditure reduction strategies
With an announced goal of saving 700 million euros, the government places this measure within the broader framework of budgetary reforms in healthcare for 2025. This part is part of a cost-saving plan that could reach up to 5.5 billion euros on healthcare expenses, involving a massive structural adjustment.
These measures respond to a context of massive financial imbalance. The Health Insurance faces a continuous increase in its expenses, with persistent risks of exceeding the ceiling at the national level. The rising costs of treatments proposed by major pharmaceutical groups such as Bayer, Novartis, GSK, Merck, or AstraZeneca also weigh on these balances.
By opting for a doubling of deductibles, the government aims both to reduce reimbursements and to promote a more frugal use of medical resources, a key aspect of controlling healthcare expenses. This action is partly justified by recurrent criticisms of the “full reimbursement” system, which does not encourage optimized use of care.
Key stakeholders affected by this reform
- 🏥 Patients, who will have to bear higher out-of-pocket costs
- 💉 Pharmacies, facing new management of deductibles and collections
- 🏦 Health Insurance, seeking budgetary recovery
- 📊 Mutuelles, largely responsible, which need to adapt their offerings
- 🏢 Pharmaceutical laboratories like Pfizer, Roche, AbbVie, Johnson & Johnson
This evolution also impacts healthcare professionals, some of whom point out administrative complexity and the risk of tensions with patients who are now more exposed to direct disbursements. According to BFMTV, implementing counter payments could also lead to disputes over administrative and financial burdens borne by pharmacies.
Consequences for patients and vulnerable groups: a risk pointed out by associations
The projected measures are likely to weigh heavily on certain already vulnerable user groups. These include notably people with long-term illnesses (ALD), who benefit from close monitoring but are not exempt from these deductibles, although specific rules apply.
Furthermore, populations such as seniors, often subjected to repeated treatments and multiple consultations, risk seeing their remaining costs significantly increase. This issue of financial accessibility to care has also been raised by unions and patient federations, such as France Asso Santé.
The double burden could also manifest for chronically ill patients who do not benefit from full exemptions, nor for families with modest incomes. These criticisms highlight an increased risk of forgoing care or delaying treatment due to costs deemed too high.
| Patient category | 2024 situation | Impact of doubling in 2025 |
|---|---|---|
| Persons with long-term illnesses (ALD) | Partially exempt, still deductibles | Risk of increased costs despite monitoring |
| Senior citizens | Multiple treatments, already heavy costs | Increased out-of-pocket, higher financial burden |
| Low-income families | Specific exemptions maintained | Potential for forgoing care due to limited resources |
| Patients without mutual insurance or non-responsible contracts | Significant out-of-pocket costs | Greater exposure to direct expenses |
In this context, several associations call for increased vigilance and open dialogue about the implementation conditions. The debate also extends to the responsibility of physicians in prescriptions and the actual effectiveness of this financial responsibility, questioning the appropriateness of placing all the burden solely on patients.
Direct payment at pharmacy counters: practical innovations and implementation challenges
The most striking novelty of this project is undoubtedly the introduction of an immediate payment of the deductible at the point of sale in pharmacies. This approach ends the principle of post-reimbursement deduction and involves the physical presence of a financial transaction.
On a technical level, this change requires adaptation of pharmacy software and internal procedures to ensure transparent management in accordance with Social Security rules. It will especially be necessary to establish precise and individualized calculation of deducted amounts within the year to avoid exceeding the mentioned ceilings.
Patients will need to pay a fixed amount at the counter, proportional to the care or medicines concerned, which could modify their purchasing behavior. This change also raises new challenges for pharmacists, who fear administrative overload and tensions with customers. It could generate resistance within the pharmacy network.
- 📋 Need for software adjustments and professional training
- ⏳ Possible slowing of pharmacy services
- 📉 Changes in patient consumption habits
- ⚠️ Risk of exclusion in case of forgetfulness or failure to pay immediately
- 💼 Impact on daily management of pharmacies
This transformation also requires effective coordination between healthcare professionals and public authorities, to prevent inefficiencies or conflicts with users. Furthermore, direct payment to physicians (flat-rate participation) could be considered, although it would add to the administrative burden on the medical sector.
Recent history of medical deductibles: progression and protests
It is important to contextualize this new step within a recent history marked by successive increases in flat-rate amounts and daily ceilings. In 2024, deductibles for medicines doubled, from 0.50€ to 1€, while those for medical transportation jumped from 2€ to 4€.
At the same time, flat-rate contributions for medical consultations and additional examinations also increased, doubling from, for example, 1€ to 2€ since May 2024.
These increases have sparked growing dissatisfaction among patients and associations, who denounce a worsening of healthcare costs contrary to the original goal of a solidarity-based system.
Until now, the government had not touched the annual ceilings, but the step taken in 2025 represents an intensification of this movement.
This dynamic raises many questions about the economic sustainability for households and the coherence of health policy, especially in a context where major pharmaceutical actors such as Sanofi or GSK play a key role in the reimbursed medicine market.
| Evolution of deductibles | Before 2024 | 2024 amount | 2025 plan |
|---|---|---|---|
| Medicine deductible | 0.50 € | 1 € | Possibility of 2 € |
| Medical transportation deductible | 2 € | 4 € | (remains 4 €) |
| Consultation flat-rate participation | 1 € | 2 € | (remains 2 €) |
| Daily ceilings | – | Double (4 € to 8 € depending on category) | (no planned change) |
Faced with protests, some government officials nonetheless emphasize the necessity of these measures within a “responsibilization” policy for users, whose results will need to be carefully evaluated.
The debate has also shifted towards the possibility of establishing deductibles on certain medical devices, a project suspended due to lack of parliamentary agreement.
The role of health mutuals in the face of rising deductibles and ceilings
Alongside these measures, health mutuals are on the front line to support insured individuals faced with the announced increase in costs. However, responsible contracts, which account for 98% of insureds, limit their capacity to cover deductibles, leaving a significant out-of-pocket burden.
For 2025, reforms are being studied to propose new health insurance products better suited to regulatory evolutions, particularly targeting seniors, a group especially affected by increased expenses.
Mutuals will notably have to:
- 💡 Rethink their offerings to better cover costs related to deductibles
- 📊 Adapt guarantees concerning annual ceilings
- 🛠️ Integrate more prevention and patient support
- 🔄 Work closely with public authorities to limit care abandonment
- 📈 Manage economic impact on contributions and the market
The discussions between the government and mutual actors, relayed by Franceinfo, show a willingness to innovate in support solutions, particularly around chronic care and innovative medicines distributed by laboratories such as AbbVie or Johnson & Johnson.
Political and social issues surrounding this reform of medical deductibles
Beyond economic and health impacts, these measures are part of a tense social and political context. The debate around reforming medical deductibles highlights essential issues: solidarity, equity, and governance of the public health system.
The reform opponents denounce an indirect increase in inequalities, pointing to an action that could weaken social cohesion. The question of patient responsibility is at the heart of the debate, with Minister Catherine Vautrin affirming that “no one chooses to be sick, but we want to make insured individuals responsible” (Le Monde).
However, trade unions like Unsa and associations like France Asso Santé question the relevance of adding financial constraints on patients without simultaneous actions on medical prescriptions.
The paradox of a system of health reputed to be universal and free that gradually introduces financial barriers challenges the very principles that founded Social Security.
- ⚖️ Debate on equity and equal access to care
- 📢 Demonstrations and possible legal recourse
- 🔄 Proposal for complementary reforms on medical prescriptions
- 📉 Risks of increased exclusion for certain populations
- 🏛️ Political pressure to preserve a balanced system
Finally, this debate also affects policymakers, who face the choice between fiscal discipline and maintaining quality and social justice. These discussions will be crucial in shaping health policies in the coming years.
Additional measures considered and alternative avenues to control healthcare costs
Beyond doubling ceilings and changing the payment mode, the government is exploring other avenues to strengthen financial recovery without excessively burdening patients.
Among these options are:
- 🏥 Reducing excessive prescriptions by increasing medical responsibility
- 📉 Limiting reimbursements for costly medical devices
- 🩺 Promoting generics and biosimilar medicines from laboratories like Novartis and Bayer
- 🔍 Fighting fraud and abuse in the healthcare system
- 📋 Optimizing care pathways through telemedicine and digital tools
Another debated avenue was the introduction of a specific deductible on medical devices such as bandages or implants, an idea estimated to potentially save up to 340 million euros. However, regulatory complexity and parliamentary opposition led to the suspension of this reform, pending further consultation.
Major pharmaceutical companies, including Roche and AstraZeneca, continue to monitor developments and adapt their commercial strategies based on government decisions.
| Envisaged measures | Objectives | Expected impacts |
|---|---|---|
| Strengthening medical prescriptions | Limit unnecessary care | Reduce unnecessary expenses |
| Promotion of generics | Lower treatment costs | Budget balancing |
| Deductible on medical devices (suspended) | Reduce associated expenses | Modest savings with low chances of adoption |
| Digital optimization of care pathways | Improve efficiency | Better coordination, fewer redundancies |
| Fraud prevention | Preserve resources | Significant gains in the medium term |
FAQ: key questions about the doubling of medical deductibles and their consequences
- ❓ What is a medical deductible?
A medical deductible is a flat sum deducted from reimbursements by Social Security for certain care and products, which the patient must finance. - ❓ Why double the annual ceilings?
The government aims to limit healthcare expenses by making patients more responsible and reducing the burden on the National Insurance. - ❓ Do mutual insurance companies cover the deductible?
No, responsible contracts that cover 98% of insured individuals do not reimburse medical deductibles. - ❓ Which patients are protected from deductibles?
Minors, beneficiaries of Complementary Health Solidarity, pregnant women from the sixth month of pregnancy, and victims of terrorism acts are exempted. - ❓ What is the impact on chronically ill and elderly patients?
They risk increased out-of-pocket costs, which could complicate access to care, requiring enhanced support.
Source: www.bfmtv.com
Entraîne-toi avec nos Quiz de révision
Fini les lectures passives. Pour retenir les notions clés du BTS Assurance, teste-toi ! Inscris-toi pour recevoir 1 quiz par jour directement dans ta boîte mail.
